Tiziana Life Sciences (TLSA)

[Steve200747909]

2.5|1 forward stock split. Is this something good or not since it seems like you are getting extra shares, same money value, seems strange they would do it at a stock price of only $10

[TREND1]

Employee Count 8

[TREND1]

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to milciclib, the Company is also developing foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody known to the company in clinical development in the world. This compound has potential application in a wide range of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

[TREND1]

TLSA CHART

[TREND1]

May be worth following

[TREND1]

PE Ratio = -0.36

[TREND1]

Float =33.28M

[TREND1]

Market Cap =350 M

[eebbee]

3.91 pre-premarket

[edwardport]

TLSA looks interesting

Tiziana Lifesciences Develops Novel Investigational Treatment For Patients Infected with COVID-19 Utilizing Direct Delivery of Anti-Interlukin-6-Receptor Monoclonal Antibodies

[ClayTrader]

* * $TLSA Video Chart 04-09-2020 * *

Link to Video - click here to watch the technical chart video

[Cheetah SPEED]

LOL

$5

[Pedro2004]

Be careful. Someone is dumping shares on the bid.

[stenick]

Why is the US disregarding a new novel il-6 inhibitor in early stage.

[canadiantrader_matt]

CEO of Tiziana doing an interview


https://ca.proactiveinvestors.com/companies/amp/news/915693?__twitter_impression=true

[ClayTrader]

* * $TLSA Video Chart 03-12-2020 * *

Link to Video - click here to watch the technical chart video

[Emptyhead]

We all knew it was coming. So there it is; an offering that values each share at roughly $.61 cents ? Hmmm...
Now why hasn't the stock cratered yet ?
Are Da Crooks looking to short against their future positions ?
Does the daily volume first have to produce at least 16,700,000 shares so insiders who
participate in the offering can Short ?
Hmmm...

[thugsam777]

3$a share 1ADSshare = to 5 regular share
so the offering is equal to .60cents a share i set my bid to 1$

[ClayTrader]

* * $TLSA Video Chart 03-11-2020 * *

Link to Video - click here to watch the technical chart video

[Expensivetaste281]

shake huh , more like falling knife

[StockRoomBully]

Shake

[Expensivetaste281]

Damn shame can’t even hold $5

[StockRoomBully]

Indeed. Folks the MAGNITUDE of the news incredible ..Shaking like crazy for shares. $15 -125 flash around 4am and 6am

This gonna be up there with mrn*

[musicbynature]

Not many shares out so could be a crazy squeeze.

Still very low market cap

TLSA

[StockRoomBully]

Big shake .. Premarket $15 - $125 lol

[Expensivetaste281]

9mil vol day on 3mil a/s , im sure it has more in the tank

[StockRoomBully]

Treatment far superior than Roche, Sanofi and Regeneron

"

Tiziana Life Sciences plc To Expedite Development of its Fully Human Anti-Interleukin-6-Receptor Monoclonal Antibody, a Potential Treatment of Certain Patients Infected with Coronavirus COVID-19 11 March 2020

New York/London, March 11, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it is expediting development of TZLS-501, a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus COVID-19 (SARS-CoV-2). Tiziana plans to administer TZLS-501 using a proprietary formulation technology. The Company entered into a world-wide license for composition-of-matter of TZLS-501, a fully human mAb targeting IL-6R, with Novimmune, SA, a Swiss biotechnology company in 2017.

Certain patients infected with coronavirus COVID-19 may develop an uncontrolled immune response (“cytokine storm”) resulting in severe damage to lung tissue which could lead to respiratory failure (see Note 1, below). Early clinical studies conducted by doctors in China suggest that anti-IL6R mAbs may be used in clinical practice for treatment of COVID-19.

Consequently, China’s National Health Commission has recommended the use of Roche’s blockbuster drug, Actemra® for treatment of patients infected with COVID-19, with serious lung damage and elevated IL-6 levels. Actemra was first approved by the FDA in 2010 for rheumatoid arthritis. Besides Actemra®, Sanofi and Regeneron are currently exploring Kevzara®, an FDA-approved anti-IL-6 receptor therapy for rheumatoid arthritis, for treatment of severe COVID-19.

Tiziana’s anti-IL-6R mAb binds to both the membrane-bound and soluble forms of IL-6R and rapidly depletes circulating levels of IL-6 in the blood (see Note 2, below). An excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness. A recent Chinese study also reported that COVID-19 infection caused clusters of severe respiratory illness such as severe acute respiratory distress syndrome (ARDS) (see Note 3, below).

“We believe that the features of TZLS-501 consisting of its dual mechanism of action to inhibit signaling by the membrane-bound and soluble IL-6 receptors along with rapid depletion of circulating IL-6 cytokine, a major cause of lung damage, provides TZLS-501 with distinct advantages for treatment of COVID-19 over other anti-IL-6R mAbs such as Actemra® and Kevzara® for treatment of COVID-19. The recent decision by researchers in China to add Actemra® to treatment guidelines for coronavirus patients with serious lung damage confirms the utility of anti-IL6R mAb. We are excited to move forward with our clinical development plan to expedite evaluation in patients as soon as possible”, said Dr. Kunwar Shailubhai, CEO & CSO of Tiziana Life Sciences.

[stockhabit]

Will we get our 1 p.m. run?

[gregque]

just bought 2day they may b 1st to market battling gilead... TLSA give us a treatment 2 day... in UK

[Expensivetaste281]

Let’s see if we can break $10 today

[StockRoomBully]

Price target $100

[stockhabit]

Just got in at 5.22

[dinogreeves]

It looks good, trading action is very weird looks like shares are hitting the market. With AS only 3 million there is only so much they can release to the market.

[crudeoil24]

Looks good! "clinical development plan" .....It would be nice if trials start within next few months. TLSA not to be confused with TSLA.

[Expensivetaste281]

Only 3mil A/S

[dinogreeves]

I don't know. Weird spike in the morning.

[Expensivetaste281]

You think it blows past $10 today?

[dinogreeves]

Market cap is very low compared to what the news is and their pipeline.

[Emptyhead]

Low Float. Recently did a 2 for 1 split. Could be explosive today.

[dinogreeves]

Market cap currently sits at 5 million even with the premarket share price increase, essentially it could go to 10 million market cap.

[dinogreeves]

New York/London, March 11, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it is expediting development of TZLS-501, a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus COVID-19 (SARS-CoV-2). Tiziana plans to administer TZLS-501 using a proprietary formulation technology. The Company entered into a world-wide license for composition-of-matter of TZLS-501, a fully human mAb targeting IL-6R, with Novimmune, SA, a Swiss biotechnology company in 2017.

Certain patients infected with coronavirus COVID-19 may develop an uncontrolled immune response (“cytokine storm”) resulting in severe damage to lung tissue which could lead to respiratory failure (see Note 1, below). Early clinical studies conducted by doctors in China suggest that anti-IL6R mAbs may be used in clinical practice for treatment of COVID-19. Consequently, China’s National Health Commission has recommended the use of Roche’s blockbuster drug, Actemra® for treatment of patients infected with COVID-19, with serious lung damage and elevated IL-6 levels. Actemra was first approved by the FDA in 2010 for rheumatoid arthritis. Besides Actemra®, Sanofi and Regeneron are currently exploring Kevzara®, an FDA-approved anti-IL-6 receptor therapy for rheumatoid arthritis, for treatment of severe COVID-19.

Tiziana’s anti-IL-6R mAb binds to both the membrane-bound and soluble forms of IL-6R and rapidly depletes circulating levels of IL-6 in the blood (see Note 2, below). An excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness. A recent Chinese study also reported that COVID-19 infection caused clusters of severe respiratory illness such as severe acute respiratory distress syndrome (ARDS) (see Note 3, below).

“We believe that the features of TZLS-501 consisting of its dual mechanism of action to inhibit signaling by the membrane-bound and soluble IL-6 receptors along with rapid depletion of circulating IL-6 cytokine, a major cause of lung damage, provides TZLS-501 with distinct advantages for treatment of COVID-19 over other anti-IL-6R mAbs such as Actemra® and Kevzara® for treatment of COVID-19. The recent decision by researchers in China to add Actemra® to treatment guidelines for coronavirus patients with serious lung damage confirms the utility of anti-IL6R mAb. We are excited to move forward with our clinical development plan to expedite evaluation in patients as soon as possible”, said Dr. Kunwar Shailubhai, CEO & CSO of Tiziana Life Sciences.

[Emptyhead]

Hmmm...

[dinogreeves]

15-20 dollars today.

[Marvy]

What's going on here

[TeddyCaswell]

Yes

[jonny_red]

3 Penny Stocks On Robinhood To Watch This Week

$TLSA $CYH $CANF

https://www.transparenttraders.me/2019/09/3-penny-stocks-on-robinhood-to-watch.html